Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway

References

• Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (New York, NY). 2014;346:945–949.
   Google Scholar
• Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141:23–31.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381:1535–1546.
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381:626–636.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–588.
   PubMed Web of Science ®Google Scholar
• Xie J, Li H, Chen L, et al. A Novel Pyroptosis-Related lncRNA Signature for Predicting the Prognosis of Skin Cutaneous Melanoma. Int J Gen Med. 2021;14:6517–6527.
   PubMed Web of Science ®Google Scholar
• Xue L, Wu P, Zhao X, et al. Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma. Int J Gen Med. 2021;14:6463–6475.
   PubMed Web of Science ®Google Scholar
• Su W, Guan Y, Huang B, et al. Bioinformatic analysis reveals hub genes and pathways that promote melanoma metastasis. BMC Cancer. 2020;20:863.
   PubMed Web of Science ®Google Scholar
• Pasteris NG, Cadle A, Logie LJ, et al. Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange factor. Cell. 1994;79:669–678.
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Chen L. EFA6 in Axon Regeneration, as a Microtubule Regulator and as a Guanine Nucleotide Exchange Factor. Cells. 2021;10:1325.
   PubMed Web of Science ®Google Scholar
• Homma Y, Hiragi S, Fukuda M. Rab family of small GTPases: an updated view on their regulation and functions. FEBS J. 2021;288:36–55.
   PubMed Web of Science ®Google Scholar
• Pedigo NG, Van Delden D, Walters L, et al. Minireview: role of genetic changes of faciogenital dysplasia protein 1 in human disease. Physiol Genomics. 2016;48:446–454.
   PubMed Web of Science ®Google Scholar
• Gorski JL, Estrada L, Hu C, et al. Skeletal-specific expression of Fgd1 during bone formation and skeletal defects in faciogenital dysplasia (FGDY; Aarskog syndrome). Dev Dyn. 2000;218:573–586.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Guo Z, Hu Z, et al. FGD1 exhibits oncogenic properties in hepatocellular carcinoma through regulating cell morphology, autophagy and mitochondrial function. Biomed Pharmacother. 2020;125:110029.
   PubMed Web of Science ®Google Scholar
• Beasley S, Buckhaults PJ, Pedigo NG, et al. Association of FGD1 polymorphisms with early-onset breast cancer. Oncol Lett. 2016;12:2071–2077.
   PubMedGoogle Scholar
• Wu W, Jing D, Meng Z, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics. 2020;10:2859–2871.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675–678.
   PubMed Web of Science ®Google Scholar
• Jeon YR, Roh H, Jung JH, et al. Antifibrotic Effects of High-Mobility Group Box 1 Protein Inhibitor (Glycyrrhizin) on Keloid Fibroblasts and Keloid Spheroids through Reduction of Autophagy and Induction of Apoptosis. Int J Mol Sci. 2019;20:4134.
   PubMed Web of Science ®Google Scholar
• Zou Z, Hu X, Luo T, et al. Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor. Nat Commun. 2021;12:2263.
   PubMed Web of Science ®Google Scholar
• Li J, Mahata B, Escobar M, et al. Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase. Nat Commun. 2021;12:896.
   PubMed Web of Science ®Google Scholar
• Wang J, Xia X, Tao X, et al. Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway. Bioengineered. 2021;12:3934–3946.
   PubMed Web of Science ®Google Scholar
• Li Y, Cheng S, Li L, et al. Light-exposure at night impairs mouse ovary development via cell apoptosis and DNA damage. Biosci Rep. 2019;39:BSR20181464.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu X, Zhang G, et al. Knockdown THOC2 suppresses the proliferation and invasion of melanoma. Bioengineered. 2019;10:635–645.
   PubMed Web of Science ®Google Scholar
• Pan M, Yin X, Huang YC. Pseudopodium enriched atypical kinase 1(PEAK1) promotes invasion and of melanoma cells by activating JAK/STAT3 signals. Bioengineered. 2021;12:5045–5055.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li J, Huang Y, et al. Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC. Cell Prolif. 2018;51:e12505.
   PubMed Web of Science ®Google Scholar
• Luan W, Ding Y, Ma S, et al. Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis. Cell Death Dis. 2019;10:855.
   PubMed Web of Science ®Google Scholar
• Chamcheu JC, Roy T, Uddin MB, et al. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: a Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells. 2019;8:803.
   PubMedGoogle Scholar
• Higuchi M, Masuyama N, Fukui Y, et al. Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells. Curr Biol. 2001;11:1958–1962.
   PubMed Web of Science ®Google Scholar
• Whitehead IP, Abe K, Gorski JL, et al. CDC42 and FGD1 cause distinct signaling and transforming activities. Mol Cell Biol. 1998;18:4689–4697.
   PubMed Web of Science ®Google Scholar
• Cai C, Xie X, Zhou J, et al. Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma. J Cell Physiol. 2020;235:611–618.
   PubMed Web of Science ®Google Scholar
• Ayala I, Giacchetti G, Caldieri G, et al. Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. Cancer Res. 2009;69:747–752.
   PubMed Web of Science ®Google Scholar
• Zagryazhskaya-Masson A, Monteiro P, Macé AS, et al. Intersection of TKS5 and FGD1/CDC42 signaling cascades directs the formation of invadopodia. J Cell Biol. 2020;219:e201910132.
   PubMed Web of Science ®Google Scholar
• Castro-Castro A, Marchesin V, Monteiro P, et al. Molecular Mechanisms of MT1-MMP-Dependent Cancer Cell Invasion. Annu Rev Cell Dev Biol. 2016;32:555–576.
   PubMed Web of Science ®Google Scholar
• Gligorijevic B, Bergman A, Condeelis J. Multiparametric classification links tumor microenvironments with tumor cell phenotype. PLoS Biol. 2014;12:e1001995.
   PubMed Web of Science ®Google Scholar
• Clark ES, Whigham AS, Yarbrough WG, et al. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007;67:4227–4235.
   PubMed Web of Science ®Google Scholar
• Stoletov K, Lewis JD. Invadopodia: a new therapeutic target to block cancer metastasis. Expert Rev Anticancer Ther. 2015;15:733–735.
   PubMed Web of Science ®Google Scholar
• Meirson T, Gil-Henn H. Targeting invadopodia for blocking breast cancer metastasis. Drug Resist Updates. 2018;39:1–17.
   PubMed Web of Science ®Google Scholar
• Luo Y, Hu J, Liu Y, et al. Invadopodia: a potential target for pancreatic cancer therapy. Crit Rev Oncol Hematol. 2021;159:103236.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204.
   PubMed Web of Science ®Google Scholar
• Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699–707.
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghadami E, Dadkhah T, et al. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234:2373–2385.
   PubMed Web of Science ®Google Scholar
• Long J, Pi X. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway. Biomed Res Int. 2020;2020:5149417.
   PubMed Web of Science ®Google Scholar
• Dang N, Meng X, Ma S, et al. MDA-19 Suppresses Progression of Melanoma Via Inhibiting the PI3K/Akt Pathway. Open Med (Wars). 2018;13:416–424.
   PubMedGoogle Scholar
• Bai M, Zhang M, Long F, et al. Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway. Oncol Rep. 2017;37:2702–2710.
   PubMed Web of Science ®Google Scholar
• Lu X, Song X, Hao X, et al. miR-186-3p attenuates the tumorigenesis of cervical cancer via targeting insulin-like growth factor 1 to suppress PI3K-Akt signaling pathway. Bioengineered. 2021;12:7079–7092.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Z, Wu Z, et al. Downregulation of the expression of the lncRNA MIAT inhibits melanoma migration and invasion through the PI3K/AKT signaling pathway. Cancer Biomarkers. 2019;24:203–211.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ma S, Ye Z, et al. MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway. J Cell Biochem. 2020;121:1283–1294.
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46:372–383.
   PubMed Web of Science ®Google Scholar
• Hou G, Xue L, Lu Z, et al. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–248.
   PubMed Web of Science ®Google Scholar
• Head SA, Shi W, Zhao L, et al. Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci U S A. 2015; 112:E7276–85.
   Google Scholar
• Werzowa J, Koehrer S, Strommer S, et al. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol. 2011;131:495–503.
   PubMed Web of Science ®Google Scholar